Company: PCRX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001104659-25-041219
Chunk: 39

Company: Pacira BioSciences, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 39
---
 | ​ | ​ | Jonathan Slonin       | ​ |
| ​ | Chief Executive Officer and Director﻿(1) | ​ | ​ | ​ | Chief Financial Officer(1) | ​ | ​ | ​ | Chief Administrative Officer and Secretary | ​ | ​ | ​ | Executive Vice President,Commercial Operations(2) | ​ | ​ | ​ | Chief Medical Officer | ​ |

| ​ | David Stack                                    | ​ | ​ | ​ | Charles A. Reinhart, III         | ​ | ​ | ​ | Lauren Riker                             | ​ | ​ | ​ |   |   |
| ​ | Former Chief ExecutiveOfficer and Chairman(3﻿) | ​ | ​ | ​ | Former ChiefFinancial Officer(4) | ​ | ​ | ​ | Former InterimChief Financial Officer(5) | ​ | ​ | ​ | ​ | ​ |

(1) Mr. Lee was appointed CEO on January 2, 2024 and Mr. Cross was appointed CFO on October 21, 2024. (2) On January 16, 2025, Mr. Gaugler was named Executive Vice President, Commercial Operations, instead of his former title as Chief Operating Officer. (3) Mr. Stack announced his retirement in September 2023 and served as Chief Executive Officer and Chairman until January 1, 2024. (4) On February 26, 2024, we and Mr. Reinhart agreed that he would depart the Company, effective September 30, 2024. (5) Ms. Riker served as interim Chief Financial Officer from October 1, 2024 to October 20, 2024. On December 20, 2023, the board appointed Frank D. Lee as chief executive officer of the Company and as a member of the board, in each case, effective January 2, 2024, and on October 21, 2024, the board appointed Shawn Cross as chief financial officer of the Company. In addition to these appointments, the board and Mr. Lee reshaped the Company’s executive team beyond its named executive officers throughout the course of 2024 and into early 2025. This Compensation Discussion and Analysis will therefore be reflective of a year of significant transition and change. For additional information, see “Compensation in Connection with Leadership Transitions” on page 71.

Pacira BioSciences, Inc. 2025 Proxy Statement | 51

TABLE OF CONTENTS Executive Compensation I